

Synthetic and Herbal Drugs Registered in Clinical Trials on COVID-19: a Review on Recent Research

Maryam Mehrabi¹, Soraya Sajadimajd¹ and Masomeh Mehrabi^{2*}

¹ Department of Biology, Faculty of Science, Razi University, Kermanshah, Iran

² Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran

ARTICLE INFO

Article history:

Received 22 April 2023

Accepted 21 June 2023

Available online 03 July 2023

Keywords:

Antibacterial drug

Antiviral drug

COVID-19

Herbal medicine

*Corresponding authors:

✉ M Mehrabi

mehrabimasomeh@yahoo.com

p-ISSN 2423-4257

e-ISSN 2588-2589

ABSTRACT

COVID-19 emerged as a widespread worldwide ailment in 2019, with a continued breakdown of novel gamma and lambda variants. Given the high incidence of COVID-19 even in the vaccinated people, research is in progress to develop convenient used drugs to control coronavirus disease. Herein, to review the effectiveness and safety of the recent antiviral, antibacterial, and herbal medication utilized to treat COVID-19, electronic databases including Scopus, PubMed, and Cochrane Library were compiled from papers registered in clinical trials on COVID-19 from January 2021 to February 2022. Oseltamivir, remdesivir, ivermectin, casirivimab, imdevimab, sotrovimab, Tocilizumab, sarilumab, dexamethasone, methylprednisolon, paxlovid, fluvoxamine, molnupiravir, ruxolitinib, tofacitinib, baricitinib, favipiravir, molnupiravir, azithromycin, niclosamide, nitazoxanide, and tetracyclines are the most commonly used antiviral and antibiotics to control mild to severe COVID-19 illnesses in the clinic. Despite the efficacy of drugs solely and in combination, medicinal herbs and natural products were considered in some clinical trials due to the high cost and unwanted side effects. However, no substantial evidence has been reported to confirm the significant anti-COVID-19 impact of synthetic and herbal medicines. This scenario opens an exciting new perspective for the elucidation of convenient therapeutic pipelines.

© 2023 UMZ. All rights reserved.

Please cite this paper as: Mehrabi, M., Sajadimajd, S., & Mehrabi, M. (2023). Synthetic and herbal drugs registered in clinical trials on COVID-19: a review on recent research. *Journal of Genetic Resources*, 9(2), 174-192. doi: 10.22080/JGR.2023.25147.1347.

Introduction

Coronavirus disease 19 (COVID-19) originated in China's Wuhan City on 31 December 2019, quickly widespread with confirmed cases in almost every country in the world, and became a prime worldwide health problem. As of 21 May 2022, globally, over 521 million confirmed cases, including almost 6.2 million deaths attributed to SARS-CoV2 infection, have been confirmed by the World Health Organization (WHO) (Fig. 1) (Hu *et al.*, 2021; WHO, 2022), making it one of the fetal pandemics to date. The majority of new confirmed cases were reported from Europe (219,393,358 cumulative cases). COVID-19 mortality is higher among men than

women, which may be attributed to females' X chromosome, which expresses immune-associated genes. Several reports have shown that about 78-85% of transmission occurs during social gatherings or between family members (Capuano *et al.*, 2020). While some parts of the world are experiencing a drop in COVID-19 cases and deaths, other parts are seeing a spike in cases. COVID-19 infection is divided by disease severity into mild, moderate, and severe illnesses, ranging from no symptoms to life-threatening. Older people or individuals with chronic health conditions will probably get severe COVID-19 disease (Cascella *et al.*, 2022).



SARS-CoV-2, as the seventh subfamily of Coronaviridae, is an enveloped, plus single-stranded RNA (+ssRNA) virus. This subfamily can be assorted into four sub-groupings: Alpha, Beta, Delta, Gamma, and Omicron-Coronaviruses, which cause severe, moderate, and mild maladies (Ko *et al.*, 2020). SARS-CoV-2 exhibits about 50% and 79.5% shared homological sequences with SARS-CoV-1 and MERS-CoV, respectively (Lu *et al.*, 2020).




Fig. 1. The cumulative number of COVID-19 cases and mortalities reported worldwide is over 197 million and the number of accumulative deaths is nearly 4.2 million, as of May 21, 2022 (WHO, 2022).

Scientists around the world have developed treatments and vaccines for COVID-19. Worldwide accessibility to COVID-19 vaccines is needed to decrease case numbers and deaths, stop the pandemic, and achieve global population immunity. Limitations in worldwide access to vaccines mean that most of the world's population remains susceptible to this virus (Samimi Nemati *et al.*, 2020). The vaccine effectiveness and duration of protection against new variants of SARS-CoV-2 remain partially understood. In summary, it is still urgent to discover more specific medications for SARS-CoV-2 infection. Until now, according to several lines of verifications, no known herbal or antiviral drugs have been supposed for the treatment of severe COVID-19. In this sense, the appropriate and most straightforward approach to producing pharmaceuticals is to exploit pre-defined and marketed medications whose characteristics, mechanisms, cytotoxicity, dosage, and promised effectiveness have been confirmed. In contrast, these drugs cannot eradicate CoVs (Tarighi *et al.*, 2021; Xu *et al.*, 2020, Fallah *et al.*, 2022).

Herbal remedies have traditionally been used to remedy viruses and infections. Still, one of the biggest problems with using these herbs is that many natural and herbal remedies are of low quality. Some of the approved herbal medicines that, according to the researchers' claim, can alleviate symptoms of COVID-19, only work as immune boosters. They may boost immunity, and the person may not be readily susceptible to infection but everyone still has to take care of themselves (Al-Kuraishy *et al.*, 2022).

Among several antiviral prescriptions suggested to treat COVID-19, remdesivir is the first antiviral FDA-approved medication utilized for COVID-19 patients (Yin *et al.*, 2020). Glucocorticoids have also shown an improvement in survival for critically ill patients. The advantage of glucocorticoids in severe COVID-19 patients confirms that the different inflammatory response is the leading cause of mortality and severity of COVID-19. More importantly, in line with the recently updated WHO guidelines, interleukin-6 receptor blockers are highly successful in increasing the life span in patients with severe COVID-19, especially when administered in combination with corticosteroids (Angriman *et al.*, 2021). In response to infection, interleukin-6 is released and stimulates inflammatory 9. Two monoclonal antibodies, sarilumab, and tocilizumab, have been identified as potential inhibitors of both soluble and membrane-bound interleukin-6 receptors. They are commonly utilized to manage inflammatory diseases, like rheumatoid arthritis and cytokine release syndrome after chimeric antigen receptor (CAR) T-cell therapy (Sujin Kang, 2021).

The network meta-analyses of clinical trials indicated that in critically or severe patients, this drug administration leads to decreased death odds by 13% compared to the standard of care (Hermine *et al.*, 2022). It suggests that there will be 15 and 28 fewer deaths, respectively, per thousand patients and every thousand severe COVID-19. Mechanical ventilation odds in severe patients are decreased by 28% compared to the standard of care. This means that 23 fewer patients per thousand require mechanical ventilation (Brown *et al.*, 2021). WHO Director (Dr. Tedros Adhanom) explained that these drugs allow people to hope for critical or severe

COVID-19 patients. Currently, IL-6 receptor blockers are unavailable throughout the world; however, it is within the power of governments and manufacturers to change that. This study reviewed treatments registered in clinical trials on COVID-19 from January 2021 to November 2022 to allocate a view of conceivably effective medications.

Synthetic drugs in clinical trials

Antiviral drugs

One of the quick ways to attenuate COVID-19 is drug repositioning, which is a unique approach to investigating the new remedial properties of existing pharmaceuticals. For this purpose, a constructive strategy for Coronavirus (CoV) monitoring is to examine the effectiveness of FDA-approved medications against new viruses (Table 1). Nevertheless, most pharmaceuticals to alleviate COVID-19 symptoms were founded on clinical follow-up instead of experimental verification. However, this does not include intense attempts toward vaccine evolution and rational drug design (Mahmoud *et al.*, 2020; Pushpakom *et al.*, 2019).

Oseltamivir

One of the concerns about developing an antiviral drug compared to an antibiotic agent development is unavoidable toxicity. Viruses are mandatory intracellular organisms that replicate mainly by recruiting a host cell's metabolic machinery present in an uninfected host cell. An antiviral drug that interferes with viral replication is likely to interfere with an essential cell function, resulting in inevitable toxicity. In traditional designing of antiviral drugs, the priority was that the drug is effective on the proteins or genetic material of the virus and has the least interaction with the host system. Oseltamivir is an example of an effective antiviral medication, which inactivates most influenza viruses due to binding to a unique enzyme on a viral protein (neuraminidase) and inhibiting it. Oseltamivir has little inhibitory effect against neuraminidase activity found in uninfected human cells, so toxicity is limited (Laborda *et al.*, 2016; Muthuri *et al.*, 2014).

Remdesivir

An RNA molecule encodes the genetic information of the coronaviruses. RNA-dependent RNA polymerase is a unique enzyme in some RNA viruses, such as SARS-CoV-2. The viral replication and disease occur by the viral RNA polymerase that constructs multiple copies of the viral RNA, which are necessary for viral particle assembly (Jiang *et al.*, 2020). Inhibition of this enzyme causes little toxicity in humans. Remdesivir is an inhibitor that binds viral polymerase and prevents viral replication. This inhibitor has homology to adenosine nucleotide structure and produces truncated RNA transcripts. In multiple clinical trials, remdesivir has been used to manage COVID-19. The FDA authorized remdesivir for in-hospital adult and child COVID-19 patients (Jiang *et al.*, 2020). The prescription of remdesivir concomitant corticosteroids has not been thoroughly studied for safety and efficacy in clinical trials; however, the combination treatment seems to be theoretically effective in severe COVID-19 (Lee *et al.*, 2021).

Chloroquine and hydroxychloroquine

Chloroquine and hydroxychloroquine earned emergency use authorization (EUA) for oral control of COVID-19 infections in hospitalized juveniles and adults on March 28. Clinical evidence in China, Italy, and France demonstrated a swift decline in COVID-19 viral load in patients who took these medications with azithromycin than in patients who did not take these drugs (Ebina-Shibuya *et al.*, 2021). When chloroquine and hydroxychloroquine received EUA for application in COVID-19 patients, it revealed these drugs might provide benefits and that the potential benefit overcomes the potential risks of adverse side effects (Abd-Elsalam *et al.*, 2020; Zou *et al.*, 2020). The EUA is distinct from FDA approval for an investigational drug. The EUA is approved following an assertion by the Secretary of Health and Human Services related to an emergency condition.

Lopinavir and/or ritonavir

It is necessary for SARS-CoV-2 replication that a polyprotein cleaves into a helicase and an RNA-dependent RNA polymerase (Zumla *et al.*, 2016). Papain-like protease (PLpro) and 3-chymotrypsin-like protease (3CLpro) are in

charge of this splitting. Lopinavir and/or ritonavir as well-known protease inhibitors are used for HIV viral disease. Nevertheless, these protease inhibitors are not recommended to treat COVID-19 infections; because results from randomized trials in patients hospitalized with COVID-19 treated with protease inhibitors darunavir/cobicistat and lopinavir/ritonavir have not demonstrated clinical efficacy in patients (Cao *et al.*, 2020; Chen *et al.*, 2020b; Consortium, 2020; Horby *et al.*, 2020).

Ivermectin

Ivermectin is one of the FDA-approved antiparasitic drugs applied for the therapy of several ancient tropical disorders including scabies, onchocerciasis, and helminthiasis (Ōmura and Crump, 2014). The weight of evidence supports that ivermectin inhibits importin alpha/beta-1 nuclear transport proteins in the host involved in intracellular uptake of the virus to increase infection by repressing the host's antiviral response (Arevalo *et al.*, 2020; Yang *et al.*, 2020). Furthermore, ivermectin anchoring seems to suppress the interaction of the SARS-CoV-2 spike protein with the host cellular membrane (Lehrer and Rheinstein, 2020). Ivermectin has been reported as a broad-spectrum antiviral agent against a dozen of viruses that develop dengue, yellow fever, HIV, and Zika (Barrows *et al.*, 2016; Tay *et al.*, 2013; Wagstaff *et al.*, 2012; Yang *et al.*, 2020). However, no reports have been published to indicate the clinical utility of ivermectin in patients with these viruses. According to some research, potential anti-inflammatory characteristics of ivermectin have also been illustrated to be effective in people with COVID-19 (Ci *et al.*, 2009; DiNicolantonio *et al.*, 2020; Zhang *et al.*, 2008). WHO Solidarity trial investigators reported that clinical trials of four reused antiviral medications including lopinavir, hydroxychloroquine, remdesivir, and interferon, indicate their inefficiency in hospitalized patients with COVID-19 (Consortium, 2020).

Sotrovimab , imdevimab and casirivimab

Sotrovimab, a recombinant monoclonal antibody, as a sole therapy and/or combination therapy of imdevimab and casirivimab, has been shown to reduce hospitalization and mortality

rates in people with COVID-19 symptoms (Gupta *et al.* 2021; Horby *et al.*, 2021). Therefore, these medications have gained Emergency Use Authorizations (EUAs) from the FDA for COVID-19 treatment in these people. Sotrovimab and imdevimab plus casirivimab remain effective against Gamma (P.1) and Beta (B.1.351) variants (Gupta *et al.*, 2021).

Tocilizumab and sarilumab

Recent evidence reveals that immunomodulatory approaches such as inhibition of IL-6 and IL-6R α signaling with tocilizumab and sarilumab are promising treatments for hospitalized COVID-19 patients (Matthay and Luetkemeyer, 2021). This treatment is based on the supposition that SARS-CoV-2 induces lung lesions through the secretion of proinflammatory cytokines. The preliminary analysis demonstrates that mortality was decreased up to 28 days after hospitalization of COVID-19 patients exposed to sarilumab and tocilizumab (as blockers of IL-6R α) compared to sufferers exposed upon usual care or placebo. More importantly, the coadministration of blockers of IL-6R α with glucocorticoids is associated with significant mortality benefits. IL-6R α blockers are accomplished for hospitalized patients who are severely or acutely sick with COVID-19 but are not yet deserved for pervasive use in patients with mild and/or severe disorders (Gordon *et al.*, 2021; Matthay and Luetkemeyer, 2021).

In a retrospective report, Vecchie *et al.* discovered that high-dose dexamethasone improves mortality and worsening respiratory function in hospitalized patients with COVID-19-related acute respiratory distress syndrome (ARDS) (Vecchié *et al.*, 2021). A well-known glucocorticoid, methylprednisolone (MP) has been reported as a convenient therapeutic strategy for hospitalized patients with COVID-19 and it is expected to have a better performance than dexamethasone in patients with hypoxic COVID-19 (Jeronimo *et al.*, 2021; Ranjbar *et al.*, 2021).

Paxlovid

Pfizer Inc.'s Paxlovid is an experimental SARS-CoV-2 protease inhibitor antiviral medication. Pfizer's oral antiviral medication, a combination of Paxlovid (PF-07321332) and ritonavir, was

given alongside molnupiravir, which is another antiviral for COVID-19. According to recent studies, Paxlovid lowered the plausibility of hospitalization or death by 89 percent. Paxlovid is intended to inhibit the action of SARSCOV-2-3Cl protease, which is required for coronavirus replication. In conjunction with a modest dosage of ritonavir, Paxlovid slows the breakdown rate of PF-07321332, allowing it to last longer throughout the body with a higher dose against the virus (Pfizer). Paxlovid does not operate as effectively when taken alone and is more effective for the coronavirus than molnupiravir since it was recognized with a novel and unique coronavirus-specific protease inhibitory activity (Wen *et al.*, 2022).

Fluvoxamine

Fluvoxamine is a selective inhibitor of serotonin reuptake (SSRI) with a high tendency to sigma-1 receptor (Calusic *et al.*, 2022). The research work led by Reis *et al.* (Reis *et al.*, 2022b) assessed 9803 prospective trial participants. In the preliminary analysis, 17 fatalities and 25 deaths were in the fluvoxamine and placebo groups, respectively. There were one and twelve fatalities, respectively, in the fluvoxamine and placebo groups with no remarkable distinction in some adverse events between the fluvoxamine and placebo groups. Fluvoxamine palliates hospitalization in high-risk outpatients with preliminary SARS-CoV2 infection. Fischer *et al.* investigated that molnupiravir is one of the earliest oral antiviral medications with an approved safety that is extremely effective at bringing down the nasopharyngeal infection of SARS-CoV-2 (Mahase, 2021a, 2021c).

Ruxolitinib

Iastrebner and colleagues conducted the study of ruxolitinib which belongs to the Janus kinase inhibitors drugs (JAK Inhibitors) that operate by competitively inhibiting the ATP-binding catalytic site on JAK1 and JAK2. The primary goal was to appraise the safety and effectiveness of ruxolitinib in SARS-CoV2 infection (Iastrebner *et al.*, 2021). Ruxolitinib had an immediate anti-inflammatory impact, and while it did not substantially diminish the ratio of pneumonia in patients with ICU and MV, the death rate was reduced ($p= 0.24$). The side effect

profile was moderate, and the study medication produced no direct organ harm. Another study examined if inhibition of cytokine signaling with ruxolitinib mediated by Janus kinase targeting led to improved hyperinflammation in ARDS progressed by SARS-CoV-2 in a non-randomized phase II multicenter research (Iastrebner *et al.*, 2021).

Tofacitinib

Guimares *et al.* (Guimarães *et al.*, 2021) Tofacitinib was discovered to be a medication with selective inhibition of Janus kinase (JAK) 1, JAK2, and JAK3 that disrupts related signaling pathways when a cytokine binds to its receptor. As a result, no cellular reaction is elicited, and cytokine production is reduced indirectly. Tofacitinib also affects the activity of IL-6 and interferons, reducing the production of cytokines by TH-1 and TH-17 cells, both of which are entailed in the pathophysiology of the ARDS. Thus, tofacitinib's effect on numerous vital pathways of the inflammatory pathways seems to relieve intensifying, lung damage derived from inflammation in hospitalized COVID-19 sufferers. Tofacitinib had a reduced risk of mortality or respiratory failure than placebo in hospitalized COVID-19 persons with pneumonia. Kalil *et al.* (Kalil *et al.*, 2021b) showed that a combination of baricitinib and remdesivir was secure and incomparable to remdesivir alone for the therapy of hospitalized individuals with COVID-19 pneumonia.

Baricitinib

Baricitinib, developed by Marconi *et al.*, is a selective inhibitor of JAK 1/2 with anti-inflammatory effects that is orally administered (Marconi *et al.*, 2021a). This trial looks at the effectiveness and safeness of baricitinib in conjunction with the standard of care (systemic corticosteroids and remdesivir) for treating COVID-19 in hospitalized patients. In the meantime, the disease progressed in some of them to a low oxygen concentration, invasive mechanical ventilation, and/or death after about one month. Although there was no substantial decrease in the overall incidence of disease advancement, therapy with baricitinib showed the same tolerability to the standard of care alone

and was linked with lower morbidity in COVID-19 hospitalized people.

Antibiotic

A main discrimination of antibiotics from viral drugs is that antibiotics can target unique metabolic pathways in bacteria that do not interfere with eukaryotic cells.

Penicillin

Some antibiotics, such as penicillin, bind to special enzymes responsible for synthesizing the bacterial cell wall (peptidoglycan); these enzymes are also named penicillin-binding proteins. The tight peptidoglycan protects bacteria against osmotic pressure (Scheffers and Pinho, 2005). Throughout the last stages of bacterial cell wall synthesis, penicillin forbids the proper formation of peptidoglycan cross-links. Loss of peptidoglycan causes lysis of the bacterium and stops its replication. Penicillin is selectively toxic to bacteria because peptidoglycan does not exist in human cells (Liu and Breukink, 2016). Furthermore, antibiotics are only effective against bacterial infections. Moreover, doctors may prescribe antibiotics for infections to fight prospective resultant bacterial infections such as bacterial pneumonia (Cox *et al.*, 2020). Concerning the WHO, antibiotics are not efficient in fighting SARS-CoV-2 infection. The inappropriate use of antibiotics for COVID-19 will intensify microbial resistance and cause more deaths throughout the disaster and ahead (Table 1).

Azithromycin

At present, azithromycin is an investigational antibiotic used by researchers as a conventional curative option for COVID-19. Azithromycin can modulate the immune response against COVID-19 by inhibiting the inflammatory system. Research also demonstrated that azithromycin has beneficial effects against Zika and Ebola viruses *in vitro*. Moreover, Azithromycin has positive effects in preventing vigorous respiratory tract bacterial complications in children infected by viruses (Gyselinck *et al.*, 2021; Venditto *et al.*, 2021).

Hydroxychloroquine

It has been suggested that examining azithromycin in combination with Hydroxychloroquine may be more effective than single therapy. In a small-scale study, the effects of azithromycin and hydroxychloroquine were investigated in persons hospitalized for COVID-19 in France. The viral load of the coronavirus was dramatically decreased by hydroxychloroquine. The concomitance of azithromycin increased the potency of hydroxychloroquine (Gyselinck *et al.*, 2021; Venditto *et al.*, 2021).

However, Rosenberg *et al.* have manifested that the use of Azithromycin with Hydroxychloroquine did not ameliorate results and increased the risk of a heart attack. This trial was accomplished on 1,438 in-hospital COVID-19 patients in New York. All contributors had homogeneous ages, races, and time to start the intervention (Rosenberg *et al.*, 2020). Accordingly, the FDA has repealed the emergency use authorization for hydroxychloroquine, so it is no longer used to remedy COVID-19.

Niclosamide and Nitazoxanide

In another study, some FDA-approved antimicrobial drugs, including niclosamide, nitazoxanide, and azithromycin, were found to have a hopeful capacity to prevent SARS-CoV-2 replication. Besides, they present the idea that several anti-inflammatory and antihistamine medications could relatively decrease SARS-CoV-2 replication (Mahmoud *et al.*, 2020; Mostafa *et al.*, 2020). Moreover, according to a docking analysis, niclosamide, nitazoxanide, and azithromycin can interact with the prime protease of SARS-CoV-2 and the binding peptide moiety of the spike protein active site, verifying that piroxicam and azithromycin co-treatment should be administered for COVID-19 patients (Mostafa *et al.*, 2020). New formulations of niclosamide including Niclosamide–Clay Intercalate Coated with Nonionic Polymer and Bovine Serum Albumin-Coated Niclosamide-Zein Nanoparticles were also associated with high efficiency in COVID-19 patients (Rejinold N *et al.*, 2021; Yu *et al.*, 2021).

Table 1. The FDA-approved medications against new virus

Anti-viral drugs	Mechanism of action	References
Remdesivir	Inhibition of viral RNA-dependent RNA polymerase	Ader <i>et al.</i> , 2022; Hamilton <i>et al.</i> , 2021
Lopinavir/ritonavir	Protease inhibitors	Cao <i>et al.</i> , 2020; Di Castelnuovo <i>et al.</i> , 2021; Horby <i>et al.</i> , 2020
Darunavir/cobicistat	Protease inhibitors	Chen <i>et al.</i> , 2020b; Di Castelnuovo <i>et al.</i> , 2021
Ivermectin	Inhibiting the host importin alpha/beta-1 nuclear transport proteins; interferes with the attachment of the SARS-CoV-2 spike protein	Abd-Elsalam <i>et al.</i> , 2021; Bryant <i>et al.</i> , 2021; Buonfrate <i>et al.</i> , 2022; DiNicolantonio <i>et al.</i> , 2020; Mohan <i>et al.</i> , 2021; Yadav <i>et al.</i> , 2021
REGEN-COV (Casirivimab plus imdevimab)	Active against Beta (B.1.351) and Gamma (P.1) variants	Horby <i>et al.</i> , 2021; O'Brien <i>et al.</i> , 2021; Weinreich <i>et al.</i> , 2021
Sotrovimab	Active against Beta (B.1.351) and Gamma (P.1) variants	Gupta <i>et al.</i> , 2021a; Gupta <i>et al.</i> , 2021b; Nagy-Agren & Vasudeva, 2021
Tocilizumab and sarilumab	Inhibition of interleukin 6 (IL-6) receptor- α subunit (IL-6R α) signaling and	Parums, 2021; Zeraatkar <i>et al.</i> , 2021
Baricitinib plus Remdesivir	Janus kinase (JAK) inhibitor and Inhibition of viral RNA-dependent RNA polymerase	Kalil <i>et al.</i> , 2021b
Baricitinib plus standard of care	Janus kinase (JAK) inhibitor and anti-inflammatory	Marconi <i>et al.</i> , 2021b
Tofacitinib	Inhibitor of the JAK-STAT pathway to lower the inflammatory response	Guimarães <i>et al.</i> , 2021
Ruxolitinib	Janus kinase inhibitors (JAK Inhibitors) and fast anti-inflammatory effect	Iastrebner <i>et al.</i> , 2021
Dexamethasone	A synthetic glucocorticoid with anti-inflammatory and immunosuppressant properties	Group, 2021; Vecchié <i>et al.</i> , 2021
Methylprednisolone	anti-inflammatory steroid	Jeronimo <i>et al.</i> , 2021; Ranjbar <i>et al.</i> , 2021
Interferon beta-1a plus remdesivir	Boosting expression and concentration of anti-inflammatory agents and decreasing the expression of pro-inflammatory cytokines and Inhibition of viral RNA-dependent RNA polymerase	Kalil <i>et al.</i> , 2021a
Favipiravir	The antiviral drug competitively inhibits RNA-dependent RNA polymerase (RdRp).	Chen <i>et al.</i> , 2020a
Molnupiravir	antiviral medicine that inhibitor of the replication of certain RNA viruses	Fischer <i>et al.</i> , 2021; Mahase, 2021a, 2021c
Paxlovid (combination of PF-07321332 and ritonavir, alongside 480 000 courses of another antiviral for COVID-19, molnupiravir)	Antiviral medicine and orally active 3C-like protease inhibitor	Mahase, 2021b
Fluvoxamine	Selective serotonin reuptake inhibitor (SSRI)	Calusic <i>et al.</i> , 2022; Lenze <i>et al.</i> , 2020; Reis <i>et al.</i> , 2022; Seftel & Boulware, 2021
Azithromycin	It prevents the replication of a COVID-19 isolate; and attaches to the main protease of COVID-19 (Protein data bank (PDB) ID: 6lu7)	Echeverría-Esnal <i>et al.</i> , 2021; Gautret <i>et al.</i> , 2021; Rosenberg <i>et al.</i> , 2020
Niclosamide; Niclosamide-clay intercalate coated with nonionic polymer; Bovine serum albumin-coated niclosamide-zein nanoparticles	It prevents the replication of a COVID-19 isolate; and attaches to the main protease of COVID-19 (Protein data bank (PDB) ID: 6lu7); hydrogen bond (HB) interaction with the key peptide moiety GLN: 493A of the spike glycoprotein active site	Pindiprolu & Pindiprolu, 2020; Rejinold N <i>et al.</i> , 2021; Romani <i>et al.</i> , 2020; Yu <i>et al.</i> , 2021
Nitazoxanide	It prevents the replication of a COVID-19 isolate; and attaches to the main protease of COVID-19 (Protein data bank (PDB) ID: 6lu7)	Mendieta Zerón <i>et al.</i> , 2021; Rocco <i>et al.</i> , 2021
Tetracyclines	Inhibitory effects on matrix metalloproteinases (MMPs); decrease the levels of inflammatory cytokines	Gironi <i>et al.</i> , 2021; Mosquera-Sulbaran & Hernández-Fonseca, 2021; Sodhi & Etminan, 2020
Lianhua Qingwen exert	Block binding of the virus with the receptor, inhibit cytokines storm, and improve clinical applications	Khan <i>et al.</i> , 2020; Liu <i>et al.</i> , 2020; Runfeng <i>et al.</i> , 2020; Shen <i>et al.</i> , 2021
Jinhua Qinggan granule	Regulation of genes co-expressed with ACE2 and immune-related signaling pathways	Liu <i>et al.</i> , 2020; Zhang <i>et al.</i> , 2021
Qingfei Touxie Fuzheng Recipe	Antiviral activity	Ding <i>et al.</i> , 2020; Jin <i>et al.</i> , 2020
<i>Withania somnifera</i> (isolated bioactive including withanone, withanoside V, withanolide A and D, withaferin A)	Blocking Mpro protease; modulation of cytokine storm and interaction with S protein	Dhawan <i>et al.</i> , 2021
<i>Myrrha gummi-resina, Hederae helioidis folium, Liquiritiae radix, Sambuci fructus</i>	Modulation of inflammatory response	Silveira <i>et al.</i> , 2020
<i>Rheu officinale Baill and Polygonum multiflorum Tunb</i> (emodin)	Modulating the angiotensin-converting enzyme 2 (ACE2) expression	Ho <i>et al.</i> , 2007
Polysaccharide and arabinogalactan fractions from medical fungi and plants	Management of immune systems	Sen <i>et al.</i> , 2021
<i>Kabasura Kudineer</i> (KSK)	Reducing viral load and preventing the disease progression	Natarajan <i>et al.</i> , 2021
<i>Nigella sativa</i> oil (NSO)	Antiviral and immunomodulatory activities	Koshak <i>et al.</i> , 2021
<i>Zuza syrup</i> (a combination of herbal medicines: <i>Nepetabraceata, Ziziphus jujube, Glycyrrhiza glabra, Ficus carica, Cordia myxa, Papaver somniferum</i> , Fennel, <i>Adiantumcapillus-veneris, Viola, Viper's-buglosses, Lavender, Iris, and sugar</i>)	Treatment of respiratory infections	Borujerdi <i>et al.</i> , 2022

Tetracycline

Tetracycline derivatives such as doxycycline are zinc-chelating agents with inhibitory effects on matrix metalloproteinases (MMPs). Coronavirus infection processes, including replication, correlate with the host MMPs complex (Humar *et al.*, 2004; Zakeri and Wright, 2008). Accordingly, this property of tetracyclines may help prevent SARS-CoV-2 infections in humans by restraining its replication within the host. Tetracyclines might also decrease inflammatory cytokines derived by SARS-CoV-2 via downregulation of the NF- κ B pathway. Furthermore, tetracyclines have been considered potential inhibitors of the main protease of SARS-CoV-2 (Wang, 2020). In this context, several researchers have recommended using tetracyclines as possible curative agents for COVID-19 therapy (Sargiacomo *et al.*, 2020; Sodhi and Etminan, 2020; Wang, 2020).

Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used for symptom relief in COVID-19. Nevertheless, there are concerns that steroidal anti-inflammatory (SAID) and non-SAID (NSAID) drugs are associated with the potential for increased harmful effects when prescribed in patients with COVID-19 (Little, 2020; Russell *et al.*, 2020). However, there have been no reports of severe damaging events in COVID-19 patients (Giollo *et al.*, 2020).

Currently, no drugs are approved by the FDA for the selective remedial way of COVID-19. Therefore, researchers are trying to find convenient pre-existing drugs and antivirals for effective therapy during the COVID-19 pandemic to get around this problem.

Herbal drugs in clinical trials on Covid-19

Owing to the severe pandemic outbreak of COVID-19 worldwide and the lack of a suitable therapeutic strategy targeting SARS-Cov2, several drugs were proposed to combat the severity of the disease (Table 1). In this line, several antivirals, anti-inflammatory, inhibitors, corticosteroids, and antibiotics, including remdesivir, lopinavir, favipiravir, hydroxychloroquine, nitric oxide, IL-6 antagonists, azithromycin as well as supplements such as ascorbic acids, zinc, and vitamin D, were

prescribed in clinics (Wu *et al.*, 2020). However, reported clinical trials have not underpinned the eventual effects of mentioned drugs in the repertoire of SARS-CoV2 infections and symptoms (Martinez, 2020).

Although the first evidence of COVID-19 was reported from China, success in the control of the disease was achieved by the middle of March 2020. In addition to the movement restrictions and social distancing, the weight of evidence supports that with standard therapies against COVID-19, multiple Chinese herbal medicines were developed and nominated by the National Health Commission (NHC, 2020). As indicated in Chinese cohort studies, patients treated with herbal and medicine standard care had a much better remission than patients exposed to solely standard care (Fang *et al.*, 2020; Shi *et al.*, 2020; Tian *et al.*, 2020; Zhang *et al.*, 2020). Purportedly, Chinese medical herbs were used as decoction and extract capsules. Most of them fall in Lianhua Qingwen exert and capsules, Jinhua Qinggan granule, and Qingfei Touxie Fuzheng Recipe (Kageyama *et al.*, 2020; Li *et al.*, 2020; Liu *et al.*, 2020; Runfeng *et al.*, 2020; Xiaojuan DING, 2020). Despite the verified efficacy and safety of Chinese herbal drugs, limited side effects such as liver dysfunction and diarrhea were reported in patients treated with Chinese medical herbs (Javorac *et al.*, 2020). In one study from Wuhan, among 293 COVID-19 inpatients, the patients treated with traditional Chinese medical herbs showed efficiency relative to only approved medical care (Wang *et al.*, 2021).

Silveira *et al.* reported several used medicinal herbs and their main ingredients for alleviation of Flu in clinical trials, including Commiphora molmol/gum (Myrrha gummi-resina), Hedera helix/leaves (Hederae heliis folium), Glycyrrhiza glabra/roots (Liquiritiae radix), and Sambucus nigra/fruits (Sambuci fructus), possess high overall benefit and safety (Silveira *et al.*, 2020). Consistent with herbs' vital role in improving COVID-19 as adjuvant and single therapy, their safety and efficacy were studied in clinical trials. For instance, one of the potential herbal drugs, Lianhuaqingwen, was reportedly assessed in case-control studies, case series, and RCTs (randomized clinical trials). According to Liu *et al.*, 924 patients with COVID-19 were exposed to Lianhuaqingwen, and the effective

rate of adjuvant therapy (RR=1.16, 95%; p=0.01) was higher than patients treated with conventional administration and single Lianhua Qingwen therapy (Liu *et al.*, 2020). In a pilot, RCT with 42 patients, the efficacy of combined treatment of Xuan fei Baidu decoction with traditional medicine was confirmed in inpatients compared to patients with convenient therapy (p<0.05). They concluded that Xuan fei Baidu decoction through modulation of inflammatory response improves patients' immunity to COVID-19 (Xiong *et al.*, 2020). *Withania somnifera* as a standard component of the Indian Ayurveda system was implied to be the most functional versus the pathogenesis of SARS-CoV-2. In addition, several steroidal lactones isolated from *W. somnifera*, including withananone and withanoside V through blocking Mpro protease, withanolide A and D via modulation of cytokine storm, and withaferin A by interaction with S protein, can treat COVID-19 (Dhawan *et al.*, 2021).

In the case of COVID-19, some phytochemicals such as emodin from *Rheum officinale* Baill and *Polygonum multiflorum* Tunb have been indicated to modulate the expression of angiotensin-converting enzyme 2 (ACE2), implying their proposed capacity in the curation of SARS-CoV2 (Ho *et al.*, 2007). Other natural products such as polysaccharide and arabinogalactan fractions from medical fungi and plants can be considered other potential agents against COVID-19 patients due to their involvement in managing immune systems. Furthermore, it seems that some anti-thromboembolic medical herbs, including *A. sativum* L. and *M. glomerata* Spreng, are effectively used drugs to improve the well-being of COVID-19 in patients (Silveira *et al.*, 2020). It is well-documented that the interaction between medical herbs and synthetic drugs can accelerate the recovery process of patients with COVID-19 (Farooq *et al.*, 2021). In line with the potential evidence from the known efficacy of 17 of 39 likely proposed medical herbs, it is suggested to use them as adjuvant therapy in COVID-19 clinical trials. It seems that they possess the potential curative impact of the SARS-CoV2 pandemic. However, other proposed herbs have not been reported evidence of their convincing in the remedy of COVID-19

and are considered herbs with unknown effects (Silveira *et al.*, 2020).

Natarajan *et al.* investigated the potency of Kabasura Kudineer (KSK) in lowering viral loads and halting disease in asymptomatic COVID-19 patients. KSK, a polyherbal compound, has historically been used to treat clinical manifestations comparable to COVID-19. KSK effectively decreased the SARS-CoV-2 viral load in asymptomatic COVID-19 cases and had no side effects, indicating that KSK should be used in the COVID-19 strategy (Natarajan *et al.*, 2020).

Koshak and colleagues conducted a clinical trial to explore the anti-COVID-19 efficacy of *Nigella sativa* oil (NSO). NSO is a natural immunomodulatory and antiviral herb recommended for the treatment of COVID-19. For individuals with mild COVID-19 infection, NSO additives led to a faster betterment of symptoms than conventional therapy alone (Koshak *et al.*, 2021).

Between March and April 2020, another study examined the efficacy of Zufa syrup (a combination of herbal medicines, including *Papaver somniferum*, *Ziziphus jujube*, *Glycyrrhiza glabra*, *Adiantum capillus-veneris*, *Ficus carica*, Fennel, *Nepeta bracteata*, *Viola*, *Viper's buglosses*, *Cordia myxa*, Lavender, and *Iris*) in the medication of suspected COVID-19. This trial enrolled patients with signs of COVID-19 on chest computed tomography who did not require hospitalization. Anxiety, dyspnea, headache, insomnia, anorexia, Cough, and myalgia steadily improved in both groups over time, with no difference between the two groups. Throughout the follow-up period, oxygen saturation and pulse rate remained steady and were comparable between study arms. Compared to the placebo, Zufa syrup did not affect symptomatology in patients with COVID-19 symptoms throughout 10 days (Borujerdi *et al.*, 2022).

Conclusions

A world pandemic of SARS-CoV2 infection has been quickly spreading, especially by developing new high pathogenic variants. As a vehicle for managing COVID-19, several effective and safe vaccines were approved to provide a high degree of protection against getting severe illness and

dying. However, by developing new variants of SARS-CoV-2 with faster spreading and more infection than earlier ones, even vaccinated people are also in danger. In addition, there are still many people who have not been vaccinated till now. Accordingly, novel therapeutic pipelines should be developed to ameliorate COVID-19 mortality. In this line, several antiviral, antibiotics, and herbal drugs were examined for COVID-19 ailment. Amid the course of clinical trials, antivirals such as remdesivir and Favipiravir as RNA polymerase inhibitors, lopinavir/ritonavir, darunavir/cobicistat, and Paxlovid as viral protease inhibitors, molnupiravir as an inhibitor of the replication of certain RNA viruses and ivermectin by inhibition of importin α/β nuclear transport protein are used in COVID-19 trials. Various small molecules such as baricitinib, tofacitinib, and ruxolitinib have been used as Janus kinase (JAK) inhibitors and fluvoxamine selective serotonin reuptake inhibitor (SSRI) in COVID-19 clinical trials (Limen et al., 2022). Antiviral monoclonal antibodies such as casirivimab, imdevimab, and sotrovimab are active against beta and gamma variants. Tocilizumab and sarilumab via inhibition of IL6Ras signaling were also prescribed for COVID-19 patients with invasive ventilation. Among antibiotics, azithromycin, niclosamide, and nitazoxanide through blockade of SARS-CoV-2 replication and blockade of proteases, tetracyclines by inhibition of host MMPs and downregulation of inflammatory cytokines are effective in the prevention of coronavirus infection. However, no drugs received approval from the FDA for the selective remedy for COVID-19, and more evidence is needed to check out the clinical and cost-usefulness of drugs. Prescription of COVID-19 patients with Chinese medicinal herbs combined with standard care has revealed much better improvement than standard care therapy. Lianhua Qingwen exerts and capsules, Jinhua Qinggan granule, Qingfei Touxie Fuzheng Recipe, from *Rheu officinale* Baill, *Polygonum multiflorum* Tunb, *Withania somnifera* ingredients, *A. satium* L., and *M. glomerata* spreng were the practical herbal therapeutics in clinical trials. It is suggested that medicinal herbs as adjuvant therapy are helpful in the treatment of COVID-19. Despite abundant

endeavors during recent months in the case of COVID-19 treatment, high-throughput screening is required to combat this global pandemic.

Acknowledgments

The authors wish to thank the Research Council of Razi University and Kermanshah University of Medical Sciences, Kermanshah, Iran.

Conflict of Interest

The authors declare no conflicts of interest.

References

- Abd-Elsalam, S., Esmail, E. S., Khalaf, M., Abdo, E. F., Medhat, M. A., Abd El Ghafar, M. S., ... & Alboraie, M. (2020). Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study. *American Journal of Tropical Medicine and Hygiene*, 103(4), 1635-1639. <https://doi.org/10.4269%2Fajtmh.20-0873>.
- Abd-Elsalam, S., Noor, R. A., Badawi, R., Khalaf, M., Esmail, E. S., Soliman, S., ... & Esmat, G. (2021). Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: a randomized controlled study. *Journal of Medical Virology*, 93(10), 5833-38. <https://doi.org/10.1002/jmv.27122>.
- Ader, F., Bouscambert-Duchamp, M., Hites, M., Peiffer-Smadja, N., Poissy, J., Belhadi, D., ... & Ribeiro, J. M. F. (2022). Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. *The Lancet Infectious Diseases*, 22(2), 209-221. [https://doi.org/10.1016/S1473-3099\(21\)004-85-0](https://doi.org/10.1016/S1473-3099(21)004-85-0).
- Al-Kuraishy, H. M., Al-Fakhrany, O. M., Elekhawwy, E., Al-Gareeb, A. I., Alorabi, M., De Waard, M., ... & Batiha, G. E. S. (2022). Traditional herbs against COVID-19: back to old weapons to combat the new pandemic. *European Journal of Medical Research*, 27(1), 186. <https://doi.org/10.1186/s40001-022-00818-5>.
- Angriman, F., Ferreyro, B. L., Burry, L., Fan, E., Ferguson, N. D., Husain, S., ... & Del Sorbo, L. (2021). Interleukin-6 receptor blockade in patients with COVID-19: placing clinical

- trials into context. *The Lancet Respiratory Medicine*, 9(6), 655-664. [https://doi.org/10.1016/S2213-2600\(21\)001-39-9](https://doi.org/10.1016/S2213-2600(21)001-39-9).
- Arevalo, A. P., Pagotto, R., Pórfido, J., Daghero, H., Segovia, M., Yamasaki, K., ... & Crispo, M. (2020). Ivermectin reduces coronavirus infection in vivo: a mouse experimental model. *BioRxiv*, 11(1), 7132. <https://doi.org/10.1101/2020.11.02.363242>.
- Barrows, N. J., Campos, R. K., Powell, S. T., Prasanth, K. R., Schott-Lerner, G., Soto-Acosta, R., ... & Garcia-Blanco, M. A. (2016). A screen of FDA-approved drugs for inhibitors of Zika virus infection. *Cell Host and Microbe*, 20(2), 259-270. <https://doi.org/10.1016/j.chom.2016.07.004>.
- Borujerdi, R., Adeli, S. H., Mohammadbeigi, A., Aliasl, F., Asghari, A., Hormati, A., ... & Asghari, M. (2022). Effects of Iranian Polyherbal Syrup (Zufa syrup) on oxygen saturation and clinical symptoms in suspected patients with COVID-19: a triple-blinded, randomized, placebo-controlled trial. *Medical Gas Research*, 12(2), 44-50. <https://doi.org/10.4103/2045-9912.325991>.
- Brown, M. J., Alazawi, W., & Kanoni, S. (2021). Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. *New England Journal of Medicine*, 385(12), 1147-1149. <https://doi.org/10.1056/nejmc2108482>.
- Bryant, A., Lawrie, T. A., Dowswell, T., Fordham, E. J., Mitchell, S., Hill, S. R., & Tham, T. C. (2021). Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. *American Journal of Therapeutics*, 28(4), e434. <https://doi.org/10.1097%2FMTJ.0000000000001402>.
- Buonfrate, D., Chesini, F., Martini, D., Roncaglioni, M. C., Fernandez, M. L. O., Alvisi, M. F., ... & Bisoffi, Z. (2022). High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial. *International Journal of Antimicrobial Agents*, 59(2), 106516. <https://doi.org/https://doi.org/10.1016/j.ijantimicag.2021.106516>.
- Calusic, M., Marcec, R., Luksa, L., Jurkovic, I., Kovac, N., Mihaljevic, S., & Likic, R. (2022). Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls. *British Journal of Clinical Pharmacology*, 88(5), 2065-2073. <https://doi.org/10.1111/bcp.15126>.
- Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., ... & Wang, C. (2020). A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. *New England Journal of Medicine*, 382(19), 1787-1799. <http://doi.org/10.1056/NEJMoa2001282>.
- Capuano, A., Rossi, F., & Paolisso, G. (2020). Covid-19 kills more men than women: an overview of possible reasons. *Frontiers in Cardiovascular Medicine*, 7, 131. <https://doi.org/10.3389/fcvm.2020.00131>.
- Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S. C., & Di Napoli, R. (2023). Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls, Treasure Island.
- Chen, C., Huang, J., Yin, P., Zhang, Y., Cheng, Z., Wu, J., ... & Wang, X. (2020a). Favipiravir versus arbidol for COVID-19: a randomized clinical trial. *MedRxiv*, 2020-03. <https://doi.org/10.1101/2020.03.17.20037432>.
- Chen, J., Xia, L., Liu, L., Xu, Q., Ling, Y., Huang, D., ... & Lu, H. (2020b). Antiviral activity and safety of darunavir/cobicistat for the treatment of COVID-19. *Open Forum Infectious Diseases*, 7(7), ofaa241. <https://doi.org/10.1093/ofid/ofaa241>.
- Ci, X., Li, H., Yu, Q., Zhang, X., Yu, L., Chen, N., ... & Deng, X. (2009). Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. *Fundamental and Clinical Pharmacology*, 23(4), 449-455. <https://doi.org/10.1111/j.1472-8206.2009.0-0684.x>.
- Consortium, W. S. T. (2020). Repurposed antiviral drugs for COVID-19-interim WHO SOLIDARITY trial results. *New England Journal of Medicine*, 384(6), 497-511. <https://doi.org/10.1056/NEJMoa2023184>.
- Cox, M. J., Loman, N., Bogaert, D., & O'Grady, J. (2020). Co-infections: potentially lethal and unexplored in COVID-19. *The Lancet*

- Microbe*, 1(1), e11. [https://doi.org/10.1016/S2666-5247\(20\)300-09-4](https://doi.org/10.1016/S2666-5247(20)300-09-4).
- Dhawan, M., Parmar, M., Sharun, K., Tiwari, R., Bilal, M., & Dhama, K. (2021). Medicinal and therapeutic potential of withanolides from *Withania somnifera* against COVID-19. *Journal of Applied Pharmaceutical Science*, 11(4), 6-13. <http://doi.org/10.7324/JAPS.2021.110402>.
- Di Castelnuovo, A., Costanzo, S., Antinori, A., Berselli, N., Blandi, L., Bonaccio, M., ... & COVID-19 RISK and Treatments (CORIST) Collaboration. (2021). Lopinavir/ritonavir and darunavir/cobicistat in hospitalized COVID-19 patients: findings from the multicenter Italian CORIST study. *Frontiers in Medicine*, 8, 639970. <https://doi.org/10.3389/fmed.2021.639970>.
- Ding, X. J., Zhang, Y., He, D. C., Zhang, M. Y., Tan, Y. J., Yu, A., ... & Liu, L. (2020). Clinical effect and mechanism of Qingfei Touxie Fuzheng recipe in the treatment of novel coronavirus pneumonia. *Herald Med*, 39(05), 640-644. [10.3870/j.issn.1004-0781.2020.05.012](https://doi.org/10.3870/j.issn.1004-0781.2020.05.012).
- DiNicolantonio, J. J., Barroso-Arranda, J., & McCarty, M. (2020). Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. *Open Heart*, 7(2), e001350. <http://doi.org/10.1136/openhrt-2020-001350>.
- Ebina-Shibuya, R., Namkoong, H., Horita, N., Kato, H., Hara, Y., Kobayashi, N., & Kaneko, T. (2021). Hydroxychloroquine and chloroquine for treatment of coronavirus disease 19 (COVID-19): a systematic review and meta-analysis of randomized and non-randomized controlled trials. *Journal of Thoracic Disease*, 13(1), 202-212. <https://doi.org/10.21037/jtd-20-2022>.
- Echeverría-Esnal, D., Martín-Ontiyuelo, C., Navarrete-Rouco, M. E., De-Antonio Cuscó, M., Ferrández, O., Horcajada, J. P., & Grau, S. (2021). Azithromycin in the treatment of COVID-19: a review. *Expert Review of Anti-infective Therapy*, 19(2), 147-163. <https://doi.org/10.1080/14787210.2020.1813024>.
- Fallah, A., Razavi Nikoo, H., Abbasi, H., Mohammad-Hasani, A., Hosseinzadeh Colagar, A., & Khosravi, A. (2022). Features of pathobiology and clinical translation of approved treatments for coronavirus disease 2019. *Intervirology*, 65(3), 119-133. <https://doi.org/10.1159/000520234>
- Fang, J., Li, H., Du, W., Yu, P., Guan, Y. Y., Ma, S. Y., ... & Bian, X. L. (2020). Efficacy of early combination therapy with lianhuaqingwen and arbidol in moderate and severe COVID-19 patients: a retrospective cohort study. *Frontiers in Pharmacology*, 11, 1465. <https://doi.org/10.3389/fphar.2020.560209>.
- Farooq, S. and Ngaini, Z., (2021). Natural and synthetic drugs as potential treatment for coronavirus disease 2019 (COVID-2019). *Chemistry Africa*, 4(1), 1-13. <https://doi.org/10.1007/s42250-020-00203-x>
- Fischer, W., Eron Jr, J. J., Holman, W., Cohen, M. S., Fang, L., Szewczyk, L. J., ... & Painter, W. P. (2021). Molnupiravir, an oral antiviral treatment for COVID-19. *MedRxiv*, 2021.06.17.21258639. <https://doi.org/10.1126/scitranslmed.abl7430>.
- Gautret, P., Lagier, J. C., Honoré, S., Colson, P., & Raoult, D. (2021). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited. *International Journal of Antimicrobial Agents*, 57(1), 106243. <https://doi.org/10.1016%2Fj.ijantimicag.2020.106243>.
- Giollo, A., Adami, G., Gatti, D., Idolazzi, L., & Rossini, M. (2020). Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID). *Annals of the Rheumatic Diseases*, 80(2), e12. <https://doi.org/10.1136/annrheumdis-2020-217598>.
- Group, R. C. (2021). Dexamethasone in hospitalized patients with Covid-19. *New England Journal of Medicine*, 384(8), 693-704. <http://doi.org/10.1056/NEJMoa2021436>.
- Guimarães, P. O., Quirk, D., Furtado, R. H., Maia, L. N., Saraiva, J. F., Antunes, M. O., ... & Berwanger, O. (2021). Tofacitinib in patients hospitalized with COVID-19 pneumonia. *New England Journal of Medicine*, 385(5), 406-415. <http://doi.org/10.1056/NEJMoa2101643>.
- Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Falci, D. R., ... & Shapiro, A. E. (2021). Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. *New England Journal of Medicine*, 385(21), 1941-1950. <http://doi.org/10.1056/NEJMoa2107934>.

- Gyselinck, I., Janssens, W., Verhamme, P., & Vos, R. (2021). Rationale for azithromycin in COVID-19: an overview of existing evidence. *BMJ Open Respiratory Research*, 8(1), e000806. <http://doi.org/10.1136/bmjresp-2020-000806>.
- Hamilton, F. W., Lee, T., Arnold, D. T., Lilford, R., & Hemming, K. (2021). Is convalescent plasma futile in COVID-19? a Bayesian re-analysis of the RECOVERY randomized controlled trial. *International Journal of Infectious Diseases*, 109, 114-117. <https://doi.org/10.1016/j.ijid.2021.06.034>.
- Hermine, O., Mariette, X., Porcher, R., Resche-Rigon, M., Tharaux, P. L., & Ravaud, P. (2022). Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. *European Respiratory Journal*, 60(2). <http://doi.org/10.1183/13993003.02523-2021>.
- Ho, T. Y., Wu, S. L., Chen, J. C., Li, C. C., & Hsiang, C. Y. (2007). Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. *Antiviral Research*, 74(2), 92-101. <https://doi.org/10.1016/j.antiviral.2006.04.014>.
- Horby, P. W., Mafham, M., Bell, J. L., Linsell, L., Staplin, N., Emberson, J., ... & Landray, M. J. (2020). Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *The Lancet*, 396(10259), 1345-52. [https://doi.org/10.1016/S0140-6736\(20\)320-13-4](https://doi.org/10.1016/S0140-6736(20)320-13-4).
- Horby, P. W., Mafham, M., Peto, L., Campbell, M., Pessoa-Amorim, G., Spata, E., . . . Hine, P. (2021). Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *MedRxiv*, 2021-06. <https://doi.org/10.1101/2021.06.15.21258542>.
- Hu, B., Guo, H., Zhou, P. and Shi, Z.L., (2021). Characteristics of SARS-CoV-2 and COVID-19. *Nature Reviews Microbiology*, 19(3), 141-154. <https://doi.org/10.1038/s41579-020-00459-7>
- Humar, A., McGilvray, I., Phillips, M. J., & Levy, G. A. (2004). Severe acute respiratory syndrome and the liver. *Hepatology* (Baltimore, Md.), 39(2), 291. <https://doi.org/10.1002/hep.20069>.
- Iastrebner, M., Castro, J., Espina, E. G., Lettieri, C., Payaslian, S., Cuesta, M. C., ... & Caruso, V. (2021). Ruxolitinib in severe covid-19 results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with covid-19 and severe acute respiratory syndrome. *Revista de la Facultad de Ciencias Médicas*, 78(3), 294-302. <https://doi.org/10.31053/10.31053%2F1853.0605.v78.n3.32800>
- Javorac, D., Grahovac, L., Manić, L., Stojilković, N., Anđelković, M., Bulat, Z., ... & Djordjevic, A. B. (2020). An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment. *Food and Chemical Toxicology*, 144, 111639. <https://doi.org/10.1016/j.fct.2020.111639>.
- Jeronimo, C. M. P., Farias, M. E. L., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., ... & Lacerda, M. V. G. (2021). Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial. *Clinical Infectious Diseases*, 72(9), e373-e381. <https://doi.org/10.1093/cid/ciaa1177>.
- Jiang, Y., Yin, W., & Xu, H. E. (2021). RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19. *Biochemical and Biophysical Research Communications*, 538, 47-53. <https://doi.org/10.1016/j.bbrc.2020.08.116>.
- Jin, L., Xu, Y., & Yuan, H. (2020). Effects of four types of integrated Chinese and Western medicines for the treatment of COVID-19 in China: a network meta-analysis. *Revista da Associação Médica Brasileira*, 66, 771-777. <https://doi.org/10.1590/1806-9282.66.6.771>.
- Kageyama, Y., Aida, K., Kawauchi, K., Morimoto, M., Ebisui, T., Akiyama, T., & Nakamura, T. (2022). Jinhua Qinggan granule, a Chinese herbal medicine against COVID-19, induces rapid changes in the neutrophil/lymphocyte ratio and plasma levels of IL-6 and IFN- γ : An open-label, single-arm pilot study. *World Academy of Sciences Journal*, 4(1), 1-8. <https://doi.org/10.3892/wasj.2021.137>.

- Kalil, A. C., Mehta, A. K., Patterson, T. F., Erdmann, N., Gomez, C. A., Jain, M. K., ... & Colombo, R. E. (2021a). Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. *The Lancet Respiratory Medicine*, 9(12), 1365-1376. [https://doi.org/10.1016/S2213-2600\(21\)00384-2](https://doi.org/10.1016/S2213-2600(21)00384-2).
- Kalil, A. C., Patterson, T. F., Mehta, A. K., Tomashek, K. M., Wolfe, C. R., Ghazaryan, V., ... & Beigel, J. H. (2021b). Baricitinib plus remdesivir for hospitalized adults with Covid-19. *New England Journal of Medicine*, 384(9), 795-807. <http://doi.org/10.1056/NEJMoa2031994>.
- Khan, S., Ali, A., Shi, H., Siddique, R., Nabi, G., Hu, J., ... & Han, G. (2020). COVID-19: Clinical aspects and therapeutics responses. *Saudi Pharmaceutical Journal*, 28(8), 1004-1008. <https://doi.org/10.1016/j.jsps.2020.06.022>.
- Ko, W. C., Rolain, J. M., Lee, N. Y., Chen, P. L., Huang, C. T., Lee, P. I., & Hsueh, P. R. (2020). Arguments in favour of remdesivir for treating SARS-CoV-2 infections. *International Journal of Antimicrobial Agents*, 55(4), 105933. <https://doi.org/10.1016/j.ijantimicag.2020.105933>.
- Koshak, A. E., Koshak, E. A., Mobeireek, A. F., Badawi, M. A., Wali, S. O., Malibary, H. M., ... & Madani, T. A. (2021). Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial. *Complementary Therapies in Medicine*, 61, 102769. <https://doi.org/https://doi.org/10.1016/j.ctim.2021.102769>.
- Laborda, P., Wang, S.-Y., & Voglmeir, J. (2016). Influenza neuraminidase inhibitors: synthetic approaches, derivatives and biological activity. *Molecules*, 21(11), 1513. <https://doi.org/10.3390/molecules21111513>.
- Lee, T. C., McDonald, E. G., Butler-Laporte, G., Harrison, L. B., Cheng, M. P., & Brophy, J. M. (2021). Remdesivir and systemic corticosteroids for the treatment of COVID-19: a Bayesian re-analysis. *International Journal of Infectious Diseases*, 104, 671-676. <https://doi.org/10.1016/j.ijid.2021.01.065>.
- Lehrer, S., & Rheinstein, P. H. (2020). Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2. *In vivo*, 34(5), 3023-3026. <https://doi.org/10.21873/invivo.12134>.
- Lenze, E. J., Mattar, C., Zorumski, C. F., Stevens, A., Schweiger, J., Nicol, G. E., ... & Reiersen, A. M. (2020). Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. *The Journal of the American Medical Association*, 324(22), 2292-2300. <https://doi.org/10.1001/jama.2020.22760>.
- Li, Z., Chen, H., Zhang, H., Li, Y., Wang, C., Bai, L., ... & Jiang, Z. (2020). Similarity and specificity of traditional Chinese medicine formulas for management of coronavirus disease 2019 and rheumatoid arthritis. *ACS Omega*, 5(47), 30519-30530. <https://doi.org/10.1021/acsomega.0c04377>.
- Limen, R. Y., Sedono, R., Sugiarto, A., & Hariyanto, T. I. (2022). Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis. *Expert Review of Anti-Infective Therapy*, 20(3), 425-434. <https://doi.org/10.1080/14787210.2021.1982695>.
- Little, P. (2020). Non-steroidal anti-inflammatory drugs and covid-19. *British Medical Journal*, 368, m1185. <https://doi.org/10.1136/bmj.m1185>.
- Liu, M., Gao, Y., Yuan, Y., Yang, K., Shi, S., Tian, J., & Zhang, J. (2021). Efficacy and safety of herbal medicine (Lianhuaqingwen) for treating COVID-19: a systematic review and meta-analysis. *Integrative Medicine Research*, 10(1), 100644. <https://doi.org/10.1016/j.imr.2020.100644>.
- Liu, Y., & Breukink, E. (2016). The membrane steps of bacterial cell wall synthesis as antibiotic targets. *Antibiotics*, 5(3), 28. <https://doi.org/10.3390/antibiotics5030028>.
- Liu, Z., Li, X., Gou, C., Li, L., Luo, X., Zhang, C., . . . Li, H. (2020). Effect of *Jinhua qinggan* granules on novel coronavirus pneumonia in patients. *Journal of Traditional Chinese Medicine*, 40(3), 467-472. <https://doi.org/10.19852/j.cnki.jtcm.2020.03.016>.
- Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., ... & Tan, W. (2020). Genomic characterisation and epidemiology of 2019

- novel coronavirus: implications for virus origins and receptor binding. *The Lancet*, 395(10224), 565-574. [https://doi.org/10.1016/S0140-6736\(20\)30251-8](https://doi.org/10.1016/S0140-6736(20)30251-8).
- Mahase, E. (2021a). Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. *British Medical Journal*, 375, n2422. <https://doi.org/10.1136/bmj.n2422>.
- Mahase, E. (2021b). Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports. *British Medical Journal*, 375, n2713. <https://doi.org/10.1136/bmj.n2713>.
- Mahase, E. (2021c). Covid-19: UK becomes first country to authorise antiviral molnupiravir. In: *British Medical Journal*, 375: n2697. <https://doi.org/10.1136/bmj.n2697>.
- Mahmoud, D. B., Shitu, Z., & Mostafa, A. (2020). Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19? *Journal of Genetic Engineering and Biotechnology*, 18, 1-10. <https://doi.org/10.1186%2Fs43141-020-00055-5>.
- Marconi, V. C., Ramanan, A. V., de Bono, S., Kartman, C. E., Krishnan, V., Liao, R., . . . de Cassia Pellegrini, R. (2021a). Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. *The Lancet Respiratory Medicine*, 9(12), 1407-1418. [https://doi.org/10.1016/S2213-2600\(21\)00331-3](https://doi.org/10.1016/S2213-2600(21)00331-3).
- Marconi, V. C., Ramanan, A. V., de Bono, S., Kartman, C. E., Krishnan, V., Liao, R., ... & Zirpe, K. (2021b). Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. *The Lancet Respiratory Medicine*, 9(12), 1407-1418. [https://doi.org/10.1016/s2213-2600\(21\)00331-3](https://doi.org/10.1016/s2213-2600(21)00331-3)
- Martinez, M. A. (2020). Clinical trials of repurposed antivirals for SARS-CoV-2. *Antimicrobial agents and chemotherapy*, 64(9), 10-1128. <https://doi.org/10.1128/aac.01101-20>
- Matthay, M. A., & Luetkemeyer, A. F. (2021). IL-6 receptor antagonist therapy for patients hospitalized for COVID-19: who, when, and how? *The Journal of the American Medical Association*, 326(6), 483-485. <https://doi.org/doi:10.1001/jama.2021.11121>
- Mendieta Zerón, H., Meneses Calderón, J., Paniagua Coria, L., Meneses Figueroa, J., Vargas Contreras, M. J., Vives Aceves, H. L., ... & Anaya Herrera, J. (2021). Nitazoxanide as an early treatment to reduce the intensity of COVID-19 outbreaks among health personnel. *World Academy of Sciences Journal*, 3(3), 1-6. <https://doi.org/10.3892/wasj.2021.94>
- Mohan, A., Tiwari, P., Suri, T. M., Mittal, S., Patel, A., Jain, A., . . . Pandey, R. M. (2021). Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a single-centre randomized, placebo-controlled trial. *Journal of Infection and Chemotherapy*, 27(12), 1743-1749. <https://doi.org/10.1016/j.jiac.2021.08.021>.
- Mosquera-Sulbaran, J. A., & Hernández-Fonseca, H. (2021). Tetracycline and viruses: a possible treatment for COVID-19? *Archives of Virology*, 166, 1-7. <https://doi.org/10.1007%2Fs00705-020-04860-8>
- Mostafa, A., Kandeil, A., AMM Elshaier, Y., Kutkat, O., Moatasim, Y., Rashad, A. A., ... & Ali, M. A. (2020). FDA-approved drugs with potent in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2. *Pharmaceuticals*, 13(12), 443. <https://doi.org/10.3390/ph13120443>
- Muthuri, S. G., Venkatesan, S., Myles, P. R., Leonardi-Bee, J., Al Khuwaitir, T. S., Al Mamun, A., ... & Nguyen-Van-Tam, J. S. (2014). Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. *The Lancet Respiratory Medicine*, 2(5), 395-404. [https://doi.org/10.1016/S2213-2600\(14\)700-41-4](https://doi.org/10.1016/S2213-2600(14)700-41-4)
- Nagy-Agren, S. E., & Vasudeva, S. S. (2021). Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BII-196 plus BII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. *Lancet Infectious Diseases*, 22(5), 622-635. [https://doi.org/10.1016/S1473-3099\(21\)007-51-9](https://doi.org/10.1016/S1473-3099(21)007-51-9)
- Natarajan, S., Anbarasi, C., Sathiyarajeswaran, P., Manickam, P., Geetha, S., Kathiravan, R., ... & Balaji, P. (2020). The efficacy of Siddha

- Medicine, Kabasura Kudineer (KSK) compared to Vitamin C & Zinc (CZ) supplementation in the management of asymptomatic COVID-19 cases: a structured summary of a study protocol for a randomised controlled trial. *Trials*, 21(1), 892. <https://doi.org/10.1186/s13063-020-04823-z>.
- National Health Commission & National Administration of Traditional Chinese Medicine. (2020). Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 7). *Chinese Medical Journal*, 133(09), 1087-1095. <https://doi.org/10.1097/CM9.0000000000000819>
- O'Brien, M. P., Forleo-Neto, E., Musser, B. J., Isa, F., Chan, K. C., Sarkar, N., ... & Weinreich, D. M. (2021). Subcutaneous REGEN-COV antibody combination to prevent Covid-19. *New England Journal of Medicine*, 385(13), 1184-1195. <https://doi.org/10.1056/NEJMoa2109682>
- Omura, S., & Crump, A. (2014). Ivermectin: panacea for resource-poor communities? *Trends in Parasitology*, 30(9), 445-455. <https://doi.org/10.1016/j.pt.2014.07.005>
- Parums, D. V. (2021). Tocilizumab, a humanized therapeutic IL-6 Receptor (IL-6R) monoclonal antibody, and future combination therapies for severe COVID-19. *Medical Science Monitor*, 27, e933973-1. <https://doi.org/10.12659/2FMMSM.933973>.
- Pindiprolu, S. K. S., & Pindiprolu, S. H. (2020). Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19. *Medical Hypotheses*, 140, 109765. <https://doi.org/10.1016/j.mehy.2020.109765>.
- Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., ... & Pirmohamed, M. (2019). Drug repurposing: progress, challenges and recommendations. *Nature Reviews Drug Discovery*, 18(1), 41-58. <https://doi.org/10.1038/nrd.2018.168>.
- Ranjbar, K., Moghadami, M., Mirahmadizadeh, A., Fallahi, M. J., Khaloo, V., Shahriarirad, R., . . . Gholampoor Saadi, M. H. (2021). Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. *BMC Infectious Diseases*, 21(1), 1-8. <https://doi.org/10.1186/s12879-021-06045-3>.
- Reis, G., dos Santos Moreira-Silva, E. A., Silva, D. C. M., Thabane, L., Milagres, A. C., Ferreira, T. S., ... & Mills, E. J. (2022). Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the together randomised, platform clinical trial. *The Lancet Global Health*, 10(1), e42-e51. [https://doi.org/10.1016/S2214-109X\(21\)00448-4](https://doi.org/10.1016/S2214-109X(21)00448-4).
- Rejinold N, S., Choi, G., Piao, H., & Choy, J. H. (2021). Bovine serum albumin-coated niclosamide-zein nanoparticles as potential injectable medicine against COVID-19. *Materials*, 14(14), 3792. <https://doi.org/10.3390/ma14143792>
- Rocco, P. R., Silva, P. L., Cruz, F. F., Melo-Junior, M. A. C., Tierno, P. F., Moura, M. A., ... & e Silva, J. R. L. (2021). Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial. *European Respiratory Journal*, 58(1): 2003725. <https://doi.org/10.1183/13993003.03725-2020>
- Romani, D., Noureddine, O., Issaoui, N., & Brandán, S. A. (2020). Properties and reactivities of niclosamide in different media, a potential antiviral to treatment of COVID-19 by using DFT calculations and molecular docking. *Biointerface Research in Applied Chemistry*, 10(6), 7295-7328. <https://doi.org/10.33263/BRIAC106.72957328>.
- Rosenberg, E. S., Dufort, E. M., Udo, T., Wilberschied, L. A., Kumar, J., Tesoriero, J., ... & Zucker, H. A. (2020). Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. *Journal of the American Medical Association*, 323(24), 2493-2502. <https://doi.org/10.1001/jama.2020.8630>.
- Runfeng, L., Yunlong, H., Jicheng, H., Weiqi, P., Qin Hai, M., Yongxia, S., ... & Zifeng, Y. (2020). Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). *Pharmacological Research*, 156, 104761. <https://doi.org/10.1016/j.phrs.2020.104761>
- Russell, B., Moss, C., Rigg, A., & Van Hemelrijck, M. (2020). COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical

- setting? *Ecancermedicalscience*, 14, 1023. <https://doi.org/10.33322/Fecancer.2020.1023>
- Samimi Nemati, A., Tafrihi, M., Sheikhi, F., Rostamian Tabari, A., & Haditabar, A. H. (2020). Designing a new multiepitope-based vaccine against COVID-19. *Research in Molecular Medicine*, 9(2), 103-118. <https://doi.org/10.1155/2020/2683286>
- Sargiacomo, C., Sotgia, F., & Lisanti, M. P. (2020). COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? *Aging (Albany NY)*, 12(8), 6511. <https://doi.org/10.18632/aging.103001>
- Scheffers, D. J., & Pinho, M. G. (2005). Bacterial cell wall synthesis: new insights from localization studies. *Microbiology and Molecular Biology Reviews*, 69(4), 585-607. <https://doi.org/10.1128/mnbr.69.4.585-607.2005>
- Seftel, D., & Boulware, D. R. (2021). Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. *Open Forum Infectious Diseases*, 8(2): ofab050. <https://doi.org/10.1093/ofid/ofab050>.
- Sen, I. K., Chakraborty, I., Mandal, A. K., Bhanja, S. K., Patra, S., & Maity, P. (2021). A review on antiviral and immunomodulatory polysaccharides from Indian medicinal plants, which may be beneficial to COVID-19 infected patients. *International Journal of Biological Macromolecules*, 181, 462-470. <https://doi.org/10.1016/j.ijbiomac.2021.03.162>
- Shen, P., Li, J., Tu, S., Wu, Y., Peng, Y., Chen, G., & Chen, C. (2021). Positive effects of Lianhuaqingwen granules in COVID-19 patients: a retrospective study of 248 cases. *Journal of Ethnopharmacology*, 278, 114220. <https://doi.org/10.1016/j.jep.2021.114220>
- Shi, N., Liu, B., Liang, N., Ma, Y., Ge, Y., Yi, H., ... & Wang, Y. (2020). Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: a retrospective multicenter cohort study. *Pharmacological Research*, 161, 105290. <https://doi.org/10.1016/j.phrs.2020.105290>
- Silveira, D., Prieto-Garcia, J. M., Boylan, F., Estrada, O., Fonseca-Bazzo, Y. M., Jamal, C. M., ... & Heinrich, M. (2020). COVID-19: is there evidence for the use of herbal medicines as adjuvant symptomatic therapy? *Frontiers in Pharmacology*, 11, 1479. <https://doi.org/10.3389/fphar.2020.581840>
- Sodhi, M., & Etminan, M. (2020). Therapeutic potential for tetracyclines in the treatment of COVID-19. *Pharmacotherapy*, 40(5), 487-488. <https://doi.org/10.1002/Fphar.2395>
- Kang, S., & Kishimoto, T. (2021). Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms. *Experimental and Molecular Medicine*, 53(7), 1116-1123. <https://doi.org/10.1038/s12276-021-00649-0>.
- Tarighi, P., Eftekhari, S., Chizari, M., Sabernavaei, M., Jafari, D., & Mirzabeigi, P. (2021). A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. *European Journal of Pharmacology*, 895, 173890. <https://doi.org/10.1016/j.ejphar.2021.173890>
- Tay, M. Y. F., Fraser, J. E., Chan, W. K. K., Moreland, N. J., Rathore, A. P., Wang, C., ... & Jans, D. A. (2013). Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. *Antiviral Research*, 99(3), 301-306. <https://doi.org/10.1016/j.antiviral.2013.06.002>
- Tian, J., Yan, S., Wang, H., Zhang, Y., Zheng, Y., Wu, H., ... & Tong, X. (2020). Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study. *Pharmacological Research*, 161, 105127. <https://doi.org/10.1016/j.phrs.2020.105127>
- Vecchié, A., Batticciotto, A., Tangianu, F., Bonaventura, A., Pennella, B., Abenante, A., ... & Dentali, F. (2021). High-dose dexamethasone treatment for COVID-19 severe acute respiratory distress syndrome: a retrospective study. *Internal and Emergency Medicine*, 16(7), 1913-1919. <https://doi.org/10.1007/s11739-021-02800-1>
- Venditto, V. J., Haydar, D., Abdel-Latif, A., Gensel, J. C., Anstead, M. I., Pitts, M. G., ... & Feola, D. J. (2021). Immunomodulatory effects of azithromycin revisited: potential applications to COVID-19. *Frontiers in Immunology*, 12, 574425. <https://doi.org/10.3389/fimmu.2021.574425>
- Wagstaff, K. M., Sivakumaran, H., Heaton, S. M., Harrich, D., & Jans, D. A. (2012).

- Ivermectin is a specific inhibitor of importin α/β -mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. *Biochemical Journal*, 443(3), 851-856. <https://doi.org/10.1042/BJ20120150>
- Wang, H., Xu, B., Zhang, Y., Duan, Y., Gao, R., He, H., ... & Li, J. (2021). Efficacy and safety of traditional Chinese medicine in coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. *Frontiers in Pharmacology*, 12, 609213. <https://doi.org/10.3389/fphar.2021.609213>
- Wang, J. (2020). Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. *Journal of Chemical Information and Modeling*, 60(6), 3277-3286. <https://doi.org/10.1021/acs.jcim.0c00179>
- Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., ... & Yancopoulos, G. D. (2021). REGEN-COV antibody combination and outcomes in outpatients with Covid-19. *New England Journal of Medicine*, 385(23), e81. <https://doi.org/10.1056/nejmoa2108163>
- Wen, W., Chen, C., Tang, J., Wang, C., Zhou, M., Cheng, Y., ... & Mao, Q. (2022). Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19 : a meta-analysis. *Annals of Medicine*, 54(1), 516-523. <https://doi.org/10.1080/07853890.2022.2034936>
- World Health Organization. (2022). Weekly epidemiological update on COVID-19. (Ed 144). [25 May 2022]. Retrieved from <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---25-may-2022>
- Wu, R., Wang, L., Kuo, H. C. D., Shannar, A., Peter, R., Chou, P. J., ... & Kong, A. N. (2020). An update on current therapeutic drugs treating COVID-19. *Current Pharmacology Reports*, 6(3), 56-70. <https://doi.org/10.1007/s40495-020-00216-7>
- Xiong, W. Z., Wang, G., Du, J., & Ai, W. (2020). Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with conventional drug in treating COVID-19: a pilot randomized clinical trial. *Integrative Medicine Research*, 9(3), 100489. <https://doi.org/10.1016/j.imr.2020.100489>
- Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., ... & Wei, H. (2020). Effective treatment of severe COVID-19 patients with tocilizumab. *Proceedings of the National Academy of Sciences*, 117(20), 10970-10975. <https://doi.org/10.1073/pnas.2005615117>
- Yadav, R., Hasan, S., Mahato, S., Celik, I., Mary, Y. S., Kumar, A., ... & Chaudhary, J. K. (2021). Molecular docking, DFT analysis, and dynamics simulation of natural bioactive compounds targeting ACE2 and TMPRSS2 dual binding sites of spike protein of SARS CoV-2. *Journal of Molecular Liquids*, 342, 116942. <https://doi.org/10.1016/j.molliq.2021.116942>
- Yang, S. N., Atkinson, S. C., Wang, C., Lee, A., Bogoyevitch, M. A., Borg, N. A., & Jans, D. A. (2020). The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β 1 heterodimer. *Antiviral Research*, 177, 104760. <https://doi.org/10.1016/j.antiviral.2020.104760>
- Yin, W., Mao, C., Luan, X., Shen, D. D., Shen, Q., Su, H., ... & Xu, H. E. (2020). Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. *Science*, 368(6498), 1499-1504. <https://doi.org/10.1126/science.abc1560>
- Yu, S., Piao, H., Rejinold, N. S., Jin, G., Choi, G., & Choy, J. H. (2021). Niclosamide-clay intercalate coated with nonionic polymer for enhanced bioavailability toward covid-19 treatment. *Polymers*, 13(7), 1044. <https://doi.org/10.3390/polym13071044>
- Zakeri, B., & Wright, G. D. (2008). Chemical biology of tetracycline antibiotics. *Biochemistry and Cell Biology*, 86(2), 124-136. <https://doi.org/10.1139/o08-002>
- Zhang, X., Song, Y., Ci, X., An, N., Ju, Y., Li, H., ... & Deng, X. (2008). Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. *Inflammation Research*, 57(11), 524-529. <https://doi.org/10.1007/s00011-008-8007-8>
- Zhang, X., Xue, Y., Chen, X., Wu, J. M., Su, Z. J., Sun, M., ... & Chen, Q. (2021). Effects of Tanreqing Capsule on the negative conversion time of nucleic acid in patients with COVID-19: a retrospective cohort study. *Journal of Integrative Medicine*, 19(1), 36-41. <https://doi.org/10.1016/j.joim.2020.10.002>

- Zhang, Y., Yao, Y., Yang, Y., & Wu, H. (2021). Investigation of anti-SARS, MERS, and COVID-19 effect of Jinhua Qinggan granules based on a network pharmacology and molecular docking approach. *Natural Product Communications*, 16(5), 1934578X211020619. <https://doi.org/10.1177/1934578X211020619>.
- Zou, L., Dai, L., Zhang, X., Zhang, Z., & Zhang, Z. (2020). Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19. *Archives of Pharmacal Research*, 43, 765-772. <https://doi.org/10.1007/s12272-020-01258-7>.
- Zumla, A., Chan, J. F., Azhar, E. I., Hui, D. S., & Yuen, K. Y. (2016). Coronaviruses-drug discovery and therapeutic options. *Nature Reviews Drug Discovery*, 15(5), 327-347. <https://doi.org/10.1038/nrd.2015.37>.